<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04758364</url>
  </required_header>
  <id_info>
    <org_study_id>60116787-020/75097</org_study_id>
    <nct_id>NCT04758364</nct_id>
  </id_info>
  <brief_title>Factors That Effect the Gait Speed in Diabetic Individuals Without Neuropathy</brief_title>
  <official_title>Factors That Effect the Gait Speed in Diabetic Individuals Without Neuropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GULIN FINDIKOGLU</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pamukkale University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study planned to investigate the role of potential explanatory factors effecting the&#xD;
      speed of gait such as muscle mass, aerobic capacity, physical activity status, cognitive&#xD;
      function, blood pressure, and metabolic measures considering age, sex, and education years in&#xD;
      diabetic individuals without neuropathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetic people will be screened by clinical symptoms of neuropathy and DN4&#xD;
      questionnaire. Among those who did not have neuropathic symptoms or who have DN4 score below&#xD;
      4 will be considered for the study.Then aerobic capacity will be measured by a cycle&#xD;
      ergometer and VO2max will be obtained. Weight, body mass index and muscle mass will be&#xD;
      measured by bioimpedance analysis. Physical activity status will be determined by&#xD;
      International Physical Activity Score (IPAQ). Cognitive function will be evaluated by Mini&#xD;
      Mental test. HbA1c and fasting blood glucose will be measured in venous blood after overnight&#xD;
      fasting. Blood pressure will be measured in the sitting position after resting from the left&#xD;
      arm. Speed of gait will be measured by an accelerometer.Then, the effect of above mentioned&#xD;
      factors on speed of gait will be studied.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 20, 2021</start_date>
  <completion_date type="Actual">March 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 12, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Month</target_duration>
  <primary_outcome>
    <measure>gait speed</measure>
    <time_frame>The gait speed will be measured once within a month after the participants enrolled.</time_frame>
    <description>gait speed measured by wearable accelerometer</description>
  </primary_outcome>
  <enrollment type="Actual">71</enrollment>
  <condition>Gait Disorder, Sensorimotor</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>measurement of gait speed</intervention_name>
    <description>Cross sectional, cohort</description>
    <other_name>measurement of aerobic capacity</other_name>
    <other_name>measurement of muscle mass</other_name>
    <other_name>measurement of blood glucose and HbA1c</other_name>
    <other_name>cognitive function testing</other_name>
    <other_name>physical activity questioning</other_name>
    <other_name>blood pressure measurement</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Type 2 Diabetic individuals without neuropathy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with Diabetes Mellitus less than 10 years but longer than 1 year&#xD;
&#xD;
          -  Absence of neuropathic symptoms&#xD;
&#xD;
          -  DN4 questionnaire sore less than 4&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Individuals who had&#xD;
&#xD;
          -  insulin therapy,&#xD;
&#xD;
          -  poor glycemic control,&#xD;
&#xD;
          -  manifesting cardiovascular disease,&#xD;
&#xD;
          -  retinopathy or other visual problems,&#xD;
&#xD;
          -  diabetic neuropathy,&#xD;
&#xD;
          -  nephropathy,&#xD;
&#xD;
          -  cerebrovascular disease,&#xD;
&#xD;
          -  cognitive impairment,&#xD;
&#xD;
          -  heart failure,&#xD;
&#xD;
          -  alcohol or cigarette dependence,&#xD;
&#xD;
          -  cancer,&#xD;
&#xD;
          -  chemo/radiotherapy,&#xD;
&#xD;
          -  foot ulcer,&#xD;
&#xD;
          -  orthopedical or surgical problems&#xD;
&#xD;
          -  wheel-chair or any assistive devices for ambulation&#xD;
&#xD;
          -  prominent knee or hip arthritis, prosthesis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pamukkale University</name>
      <address>
        <city>Denizli</city>
        <zip>21600</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2021</study_first_posted>
  <last_update_submitted>March 30, 2021</last_update_submitted>
  <last_update_submitted_qc>March 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Pamukkale University</investigator_affiliation>
    <investigator_full_name>GULIN FINDIKOGLU</investigator_full_name>
    <investigator_title>Assoc Proffessor, MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Mini-Mental State Examination</keyword>
  <keyword>gait</keyword>
  <keyword>aerobic capacity</keyword>
  <keyword>HbA1c</keyword>
  <keyword>muscle</keyword>
  <keyword>hypertension</keyword>
  <keyword>glucose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gait Disorders, Neurologic</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

